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Abstract
DSCR1/ RCAN1 is a chromosome 21 gene found to be overexpressed in the brains of Down syndrome (DS) and postulated as
a good candidate to contribute to mental disability. However, even though Rcan1 knockout mice have pronounced spatial
learning and memory deficits, the possible deleterious effects of its overexpression in DS are not well understood. We have
generated a transgenic mouse model overexpressing DSCR1/RCAN1 in the brain and analyzed the effect of RCAN1
overexpression on cognitive function. TgRCAN1 mice present a marked disruption of the learning process in a visuo-spatial
learning task. However, no significant differences were observed in the performance of the memory phase of the test
(removal session) nor in a step-down passive avoidance task, thus suggesting that once learning has been established, the
animals are able to consolidate the information in the longer term.
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Introduction
Mental disability in individuals with Down syndrome (DS) is
produced by the increased expression of some of the 231
supernumerary genes on the extra copy of chromosome 21. One
such gene is Down’s syndrome candidate region-1 (DSCR1, also
known as RCAN1) [1,2], which encodes a protein that is a
functional inhibitor of calcineurin, a ubiquitous and multifunc-
tional calcium-activated protein phosphatase. It is located in the
Down syndrome critical region and its expression is consistently
increased 1.8-fold in Down’s syndrome human fetal tissues and in
Ts65Dn mice [3].
RCAN1 physically and functionally interacts with calcineurin
A, effectively inhibiting its phosphatase activity [4]. Calcineurin is
the most abundant protein in brain where it regulates, among
other neuronal functions, neurotransmitter release, neurite
outgrowth and neuronal cell death. The only calcineurin inhibitor
which expression is regulated by calcium-calcineurin signaling is
RCAN1, indicating that this protein can function in a feedback
inhibition loop to suppress sustained calcineurin activity. RCAN1
is widely expressed in brain, both during development and in the
adult and it has been postulated as a good candidate to contribute
to mental disability in DS [5,6,7]. Mouse models of RCAN1
overexpression have shown a role of RCAN1 regulating exocytosis
in chromaffin cells and in mutant huntingtin phosphorilation,
suggesting a role of RCAN1 in the Alzheimer’s disease
neuropathology associated to DS and in Huntington’s disease
[8,9,10]. Moreover, it has been identified as a gene involved in
cognitive symptoms of schizophrenia patients by measuring
differences in DNA copy number variants [11]. Evidences of an
RCAN1 role in cognition also exist from studies in experimental
models. Drosophila mutants with both loss-of-function or overex-
pression of nebula exhibit severe learning defects that are
attributed by biochemical perturbations rather than maldevelop-
ment of the brain [12] and the Rcan1 knockout mice present
pronounced spatial learning and memory deficits in the Morris
water maze task and impaired long-term potentiation (LTP) [13].
However, the in vivo relevance of Rcan1 overexpression and its
possible contribution to DS cognitive phenotypes has not yet been
explored.
In the current study we have analyzed the effect of RCAN1
overexpression on the cognitive function using transgenic mice.
We have focused on the potential role of this regulator in processes
related to learning and memory in DS by characterizing the
neurological and cognitive alterations in these mice. Our work
confirms a role of RCAN1 overexpression in the visuo-spatial
learning and memory tasks, with alterations similar to those
present in DS persons.
Materials and Methods
Generation of TgRCAN1 transgenic mice
The transgenic cassette was generated by cloning a 1.3 Kb
fragment of the human PDGFb chain promoter in the 59 region of
a plasmid containing the second intron of the b-globin gene,
flanked by part of exons 2 and 3, and the polyadenilation signal of
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EcoRI site of the b-globin exon 3. The complete cassette was
sequenced with specific primers in an automated sequencer
(Applied Biosystems 373A) to ensure the integrity of the transgene.
The PDGFb-RCAN1 construct was isolated from the plasmid
sequences by digestion with XbaI and XhoI, gel purified using the
GenClean spin kit (Q-Biogene) and microinjected (2–5 mg/ml)
into B6/SJL zygotes, which were transferred to the oviducts of
0.5 dpc pseudopregnant CD1 females. Genotyping of founder
mice was performed by Southern blotting. Genomic DNA was
obtained from mice tail biopsy. Ten mg of DNA were digested with
EcoRI, electrophoresed in 1% agarose and transferred to
nitrocellulose membranes (Hybond-N+; Amersham Pharmacia
Biotech). Hybridization of the filters was done according to
manufacturer procedures (Amersham Pharmacia Biotech), using
the human RCAN1 cDNAs as a probe. Three transgenic lines were
obtained and maintained in hemizygosity by crossing with B6/SJL
mice. Transgene copy number was also determined by Southern
blot analysis. Autoradiographies were analyzed using Phoretix 1D
software (Nonlinear Dynamics Ltd, Newcastle Upon Tyne, UK).
Genotyping of the progeny was performed by multiplex PCR
analysis using the human specific primer pairs: RCAN1-F primer,
59- AGGACGTATGACAAGGACAT -39 and RCAN1-R primer,
59-ATCAGAAACTGCTTGTCTGGA-39; GdX-F primer, 59-
GGCAGCTGATCTCCAAAGTCCTGG-39 and GdX-R prim-
er, 59- AACGTTCGATGTCATCCAGTGTTA -39. PCR con-
ditions were denaturation at 94uC for 15 sec, annealing at 56uC
for 15 sec, and extension at 72uC for 30 sec, for 32 cycles.
RT-PCR analysis
Total RNA was prepared from different brain regions
(hippocampus, cerebral cortex and cerebellum) of TgRCAN1 and
control mice using TriPure reagent (Roche). To avoid genomic
contamination RNA samples were treated with DNAse (DNAfree,
Ambion), as described by manufacturer’s protocol. One mg of total
RNA from each sample was reverse transcribed with a Retroscript
RT kit (Ambion). Two ml of cDNA was PCR amplified with the
same conditions described above for genotyping with the human
specific primers (RCAN1-F and RCAN1-R). Absence of genomic
DNA contamination was determined by the amplification of a
126 bp PCR fragment from cDNA samples with primers for GdX
transcript (GdX-F and GdX-R).
Western blot analysis
Western blot analysis from adult brain samples was performed
as described by Porta et al. with minor modifications [5]. Briefly,
individual samples were mechanically homogenized in a glass
potter, with a lysis buffer, containing: 50 mM Tris-HCl pH 7.4,
10 mM EDTA, 320 mM sucrose, 1 mM phenylmethylsulfonyl
fluoride and a protease inhibitor cocktail (Complete Mini, Roche
Diagnostics, Mannheim, Germany). Extracts were centrifuged for
10 min at 8006g for 10 min at 4uC, and the protein concentration
determined from the cleared lysate (BCA assay; Pierce, Rockford,
IL). Proteins were separated by 12% SDS-PAGE gel and
transferred onto nitrocellulose membranes (HybondTM-C, Amer-
sham Biosciences, Freiburg, Germany). The membranes were
blocked in 10% non-fat dried milk dissolved in TBS-T (10 mM
Tris-HCl pH 7.5, 100 mM NaCl, 0,1% Tween 20) for 1 h at
room temperature and then incubated overnight at 4uC with the
primary antibody, a rabbit polyclonal anti-RCAN1 [5], diluted
1:1000 in 5% powdered milk in TBS-T. Protein loading was
monitored using a mouse antibody against a-tubulin (1:5000,
Sigma). Incubation with anti-rabbit or anti-mouse IgG/HRP
(horseradish peroxidase) antibodies (1:2000; Dako, Glostrup,
Denmark) was performed at room temperature for 1 h. Mem-
branes were rinsed in PBS-T and the immunocomplexes were
detected by enhanced chemiluminiscence with ECL
TM Western
blotting detection reagent (Amersham Bioscience). Chemiluminis-
cence was determined with a LAS-3000 image analyzer (Fuji
PhotoFilm Co., Carrollton, TX, USA).
General histology
Mice were anaesthetized and then perfused transcardially with
0.1 M PBS, followed by chilled 4% paraformaldehyde in PBS. At
least five animals were used per genotype and age. Brains were
removed from the skull and postfixed in the same fixative for 24 h
at 4uC overnight. After rinsing in PBS, brains of adult mice were
cryoprotected in 30% sucrose and kept frozen at 280uC. Coronal
sections 50 mm thick were cut with a cryostat and maintained in
cryoprotective solution at 220uC until use. Sections were mounted
in slices, air-dried, dehydrated in increasing concentrations of
ethanol followed by xilene and coverslipped with DPX mounting
medium. Cresyl violet staining was performed to determine the
total cell population.
Behavioral analysis
Animals. Transgenic mice were obtained in heterozygosity in
B6/SJL-F1J genetic background. Hybrid founders were crossed
using B6/SJL-F1J females and all experiments were performed
using mice from the F1–F5 generation to attenuate littermate’s
genetic differences. We have used male mice in order to avoid
female estrous cycle variations. The non-transgenic (WT)
littermates obtained from crosses of males TgRCAN1 mice and
B6/SJL-F1J females served as controls. Mice were housed in
groups of 3–5 animals per cage in standard macrolon cages (40 cm
long625 cm wide620 cm high) under a 12 h light/dark schedule
(lights on 08:00 to 20:00) in controlled environmental conditions of
humidity (50%–70%) and temperature (2262uC) with food and
water supplied ad libitum. All experimental procedures were
approved by the local ethical committee (CEEA-IMIM and
CEEA-PRBB), and met the guidelines of the local (Catalan law 5/
1995 and Decrees 214/97, 32/2007) and European regulations
(EU directives 86/609 and 2001-486) and the Standards for Use of
Laboratory Animals nu A5388-01 (NIH).
Neurological assessment (SHIRPA protocol). A
comprehensive testing protocol was used to identify and
characterize phenotype impairments as previously described
[14,15]. Assessment of each animal began with observation of
undisturbed behavior in a cylindrical clear Perspex viewing jar
(15 cm height611 cm diameter) for wild running or stereotypy.
The mice were then transferred to an arena (56634 cm) for
observation of motor behavior and sensorial function. Animals
underwent screening exams for visual acuity, vibrissae, corneal
and pinna responses to an approaching cotton swab, auditory
function (Preyer reflex), vestibular function (contact righting reflex
and negative geotaxis), and grip strength and body tone. In the last
part of the test, changes in excitability, aggression, general fear,
vocalization and salivation and piloerection (for analysis of
autonomic function) were recorded.
Coat-hanger test. Motor coordination was initially
measured using the coat-hanger test, placing the mice in the
middle of the wire in an upside-down position. First, the prehensile
reflex was evaluated and was rated as (0) if the mouse fell off the
hanger and as (1) if it remained hanging during a 5 sec period.
During this period traction capacity was rated as (0) if mice did not
lifted-up their hind limbs, (1) if they lifted one of the hind limbs, (2)
if they lifted both, and (3) if they reached one of the ends of the
hanger. After this initial evaluation, the latency to fall, time to
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performed on the wire was measured in a single trial lasting 60 sec.
Balance beam test. The ability of the mice to maintain
balance was evaluated on a wooden bar (9 cm diameter650 cm
long612 mm thick) during a period of 40 sec. Mice were placed
with their forelimbs on the bar and two trials were performed. The
score was rated as follows: (0) if the mouse fell before the 40 sec
period; (1) if the mouse remained in the center of the bar; (2) if it
moved out of the center, but it did not reach the ends; (3) if it
reached one of the ends.
Open field. The open field was a white Plexiglas apparatus
(70 cm wide670 cm long625 cm high) divided into 25 equal
squares, it were delimited with black lines on the white floor of the
box and under high intensity light levels (300 luxes). Two zones,
the centre and periphery, were delineated being the centre more
anxiogenic. At the beginning of the test session, mice were left in
the middle of the apparatus and the latency to cross from the
centre to the periphery, the distance traveled, velocity and time
spent in each zone and rearing activity, defecation (number of
fecal boluses) and grooming behavior were scored during 5 min.
Rotating rod test. To test motor coordination and balance,
the ability of each mouse to maintain balance was assessed on a
rotating rod (5 cm diameter610 cm long) with a plastic dowel
surface (Rotarod LE8500, Panlab SA, Barcelona, Spain). The
equipment consisted of a rotating spindle that is able to maintain a
fixed rotational speed (revolutions per min, rpm) and to undergo
an acceleration cycle, starting at 4 rpm and accelerating at a
constant rate to 40 rpm over a 1 min period. The apparatus is
provided with magnetic plates to detect when a mouse has fallen
off the rod. Mice were placed on the middle of the rotating rod, its
body axis being perpendicular to the rotation axis, and its head
against the direction of rotation. All animals were tested for
acquisition and maintenance of rotating performance. The
experimental design consisted of two training sessions (day 1 and
2) in which the number of trials required to learn to remain on the
rod during 180 sec at the minimum speed (4 rpm) was recorded.
After the mice reached the criterion, a third session (day 3) was
carried out in which two different tasks were performed: motor
coordination and balance were assessed (a) by measuring the
latency to fall off the rod in consecutive trials with increasing fixed
rotational speeds (7, 10, 14, 19, 24, and 34 rpm), and the animals
were allowed to stay on the rod for a maximum period of 240 sec
per trial and a resting period of 15 min was left between trials; and
(b) for the accelerating rod test, the rotation speed was increased
during a single session of 60 sec from 4 to 40 rpm. For each trial,
the elapsed time until the mouse fell off the rod was recorded.
Visuo-spatial learning and memory in the water maze
test. To test hippocampal-dependent spatial cognition,
TgRCAN1 mice were trained in the standard Morris water maze
(MWM) with a hidden platform as previously described [16]. The
mice were tested over 6 days (4 trials/session, 10 min inter-trial
intervals). The water maze consisted of a circular pool (diameter,
1.20 m; height, 0.5 m). It was filled with tepid water (24uC)
opacified by the addition of powdered milk (0.9 kg). A white
escape platform (15 cm diameter, height 24 cm) was located 1 cm
below the water surface in a fixed position (NE quadrant, 22 cm
away from the wall). In each trial, mice were placed at one of the
starting locations in random order [north, south, east, west (N, S,
E, W), including permutations of the four starting points per
session] and were allowed to swim until they located the platform.
Mice failing to find the platform within 60 sec were placed on it
for 20 sec (the same period of time as the successful animals). At
the end of every trial the mice were allowed to dry for 15 min in a
heated enclosure and were returned to their home cage. The cue
session was performed to test the swimming speed and visual
ability using the visible platform, elevated 1 cm above the water
and its position was clearly indicated by a visible cue (black flag).
White curtains with affixed black patterns to provide an
arrangement of spatial cues surrounded the maze. It was
performed 24 hours after the fourth training sessions and 5 days
after completion of the hidden platform training protocol. To test
whether the mice remembered the location of the platform, probe
trials were performed. In the probe session the platform was
removed and mice were allowed to swim for 60 sec. The time
spent in the trained and non-trained quadrants as well as the
number of platform annulus crossings during 60 sec were
recorded. On the next day (5 days after the last acquisition
session), mice performed the reversal learning session. In this test,
the platform position was changed to the opposite quadrant (SW).
All the trials were recorded and traced with an image tracking
system (SMART, Panlab, Spain) connected to a video camera
placed above the pool. Escape latencies, length of the swimming
paths and swimming speed for each animal and trial were
monitored and computed. The more in detail analysis of the
performance of the mice, was performed using a custom-designed
analysis program the jTracks software [17].
Passive Avoidance. We used a step-down passive avoidance
test, which consisted of a transparent Plexiglas circular cage
(40 cm in height, 30 cm in diameter) with a grid floor and a
circular platform (4 cm diameter) in the center. During the
training session, animals were placed on the platform and their
latency to step down with all four paws was measured.
Immediately after stepping down on the grid, animals received
an electric shock (0.6 mA, 2 sec). Retention test sessions were
carried out 24 h (short-term) and 7 days after training (long-term).
Step-down latency was used as a measure of memory retention. A
cut-off time of 300 sec was set.
Data analysis
Simple comparisons between TgRCAN1 and control mice in
various tasks were performed using the two-tailed unpaired
Student t test with Mann-Withney’s correction to account for
the different variances in the populations being studied. Perfor-
mances on the Rotarod were compared using repeated measures
ANOVA. To assess significant differences in the behavior of both
transgenic lines a one-way ANOVA with Bonferroni test for post
hoc analyses was performed. In the Morris Water Maze a repeated
measures ANOVA test was used. The passive avoidance test was
analyzed using Mann-Withney U non-parametric test. Data were
summarized as mean 6 standard error of mean (S.E.M.). In all
tests, a difference was considered to be significant if the obtained
probability value was P,0.05. The statistical analysis was
performed using the SPSS 12.0 software.
Results
TgRCAN1 mice are viable and show no gross abnormal
phenotype
To generate the transgenic mice TgRCAN1, the human isoform
splice variant 1 was placed under the control of the PDGFb
promoter to drive transgene expression to brain areas [18,19]
(Fig. 1A). Three transgenic lines were generated (Fig. 1B) that
expressed the human RCAN1 isoform in the brain regions
analyzed, being more abundant in the hippocampus and cerebral
cortex as shown by RT-PCR (Fig. 1C). No expression of
hRCAN1 was detected in WT mice. Western blot analysis
confirmed RCAN1 overexpression that was estimated in 1.3-fold
and 1.5-fold in the hippocampus and cerebral cortex respectively
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genotypes were observed in terms of viability. Neurological
assesment using the comprehensive SHIRPA protocol did not
reveal any differences between TgRCAN1 and the control
littermates, suggesting no gross impairment in general neural
function. The observational assessment of behaviour in basal
conditions showed no changes in excitability, fear, or aggressive
behaviour (Table 1). General histological staining did not reveal
gross abnormalities in TgRCAN1 brains.
Sensorimotor evaluation
TgRCAN1 mice did not show differences in the performance of
a battery of sensorimotor tasks. No significant differences were
attained in traction capacity (x
2 Pearson=3.364, P=0.762, data
not shown), or when measuring the prehensile reflex, as shown by
the similar latencies to fall in the 5 sec trial (F(1, 54)=0.866,
P=0.356, ANOVA). Similarly, in the balance beam test, the
latencies to fall during 40 sec did not differ between genotypes
(F(1, 54)=0.006, P=0.938, ANOVA) thus suggesting that neither
balance nor muscular strength were affected by RCAN1
overexpression. Also, no genotype-dependent differences were
observed in the execution of the rotarod task (Fig. 2), neither
during the training sessions (T1, T2), nor in the constant rotational
speed sessions at low rpm (F(1, 10)=2.296, P=0.161, MANOVA).
However, at higher speed TgRCAN1 performed significantly
worse than wild types (latency to fall from the rod at 24 rpm
Figure 1. Genotyping and expression analysis of TgRCAN1 mice. A) Schematic representation of the PDGFb/RCAN1 chimeric gene. B)
Southern blot analysis of three independent transgenic lines (L21, L27 and L37). C) Expression of the transgene by RT-PCR analysis in hippocampus
(Hp), cerebral cortex (Cx) and cerebellum (Cb) of TgRCAN1 and control mice. D) Western blot analysis and relative quantification of RCAN1 protein
levels from adult wild type (WT n=6) and transgenic mice (TgL37 n=8), in cerebral cortex and hippocampus. a-Tubulin was used as an internal
loading control. Bars show densitometric analysis of Rcan1 normalized against the a-tubulin band (Hp: hippocampus, Cx: cerebral cortex). Data are
represented as mean 6 S.E.M. *P,0.05, Student’s t test.
doi:10.1371/journal.pone.0017010.g001
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dependent on motor coordination since the more demanding
acceleration trials showed no differences between genotypes
(F(1, 11)=0.915, P=0.359, ANOVA).
Open Field
In the open field, TgRCAN1 mice showed a tendency to
hyperactivity with increased distance travelled in the periphery
(F(1, 11)=3.550, P=0.086, ANOVA, data not shown), along
with an increase in the mean speed found in TgRCAN1 mice
(F(1, 11)=2.544, P=0.139, ANOVA) This phenotype probably
reflects a higher anxiety level since the mice showed no increase in
the distance traveled in the center.
Morris Water Maze
We used the standard paradigm of the Morris water maze to
analyze the visuo-spatial learning and memory profile in
TgRCAN1 mice (Fig. 3). No genotype-related differences were
observed in the training session, as demonstrated by the similar
escape latency (ANOVA, F(1,25)=2.96; P=0.87) and distance
travelled (data not shown), although a tendency to perform worse
the procedural learning task was detected in transgenic mice.
Along the acquisition sessions, all groups of animals were efficient
in learning the location of the platform as indicated by the
progressive decrease in escape latency (repeated measures
ANOVA, wild type, F(1,23)=100.7, P=0.0001; TgRCAN1,
F(1,16)=110.5, P=0.0001) and distance travelled (repeated
measures ANOVA, P,0.001). However, an important learning
impairment was detected in TgRCAN1 (repeated measures
ANOVA, ‘‘session6genotype’’, F(1,28)=14.11, P,0.001) mice as
shown by the increased latencies (Fig. 3, left panel) to reach the
platform and distances (repeated measures ANOVA, ‘‘session6
genotype’’, F(1,28)=16.14, P,0.001) Fig. 3, right panel) travelled
across acquisition sessions. This was specifically related to learning
problems since swimming speed was not affected and in the cued
session, where the goal was to find a visible platform (black
stripped flag), no differences were detected in the latency to reach
the platform when it was made visible (ANOVA, F(1,40)=1.08;
P=0.31) suggesting that RCAN1 overexpression did not produce
significant motor or motivational problems. During the probe trial
that is a measure of the visuo-spatial memory, the latency to cross
the annulus of the hidden escape platform and the number of
crosses was similar between genotypes thus suggesting that once
learned the information is retained in transgenic mice. Moreover,
in both groups we observed a significantly higher preference for
the trained quadrant (northwest), as shown by the percentage of
time spent in the trained quadrant (ANOVA, wild-type,
F(1,23)=58.6, P=0.001 and TgRCAN1,F (1,16)=56.7, P=0.001).
These observations support the conclusion that TgRCAN1 mice
indeed remember the location of the platform. Finally, in the
reversal session the efficiency to unlearn the old platform position
and learn a new one was not altered in TgRCAN1.
Passive avoidance test
To further explore the learning and memory phenotypes, we
used a step down passive avoidance paradigm. Retention memory
was not altered either 24 hours or one week after training in
transgenic mice, both genotypes showing increased retention
latencies. This indicates that memory consolidation had taken
place (data not shown).
Discussion
Efforts to identify genes on human chromosome 21 with the
potential to cause the brain anomalies observed in Down
syndrome (DS), led to the discovery of a gene, Down syndrome
candidate region-1 (DSCR1) now renamed RCAN1 (Regulator of
Calcineurin-1). RCAN1 is a modulator of calcineurin, a protein
phosphatase known to function in a variety of cellular processes,
among which learning and memory are relevant for the mental
impairment seen in DS. Specifically, Hoeffer et al [13] reported
that Rcan1 knockout mice have pronounced spatial learning and
memory deficits in the Morris water maze task, along with
significant deficits in long-term potentiation (LTP) in the
hippocampal area CA1, similar to what was found in mice with
inducible, hippocampal-restricted overexpression of constitutively
active calcineurin [20]. In animals in which calcineurin was
inhibited by either transgenic expression of a calcineurin inhibitory
domain or application of antisense oligonucleotides [21,22] the
opposite phenotypes were detected, thus suggesting that RCAN1
provides a constraint on calcineurin activity during learning and
memory.
Table 1. SHIRPA primary behavioral screen.
WT TgRCAN1 P
Piloerection
Absent 60% 75% NS
Present 40% 25% NS
Tail Elevation
Horizontally extended 80% 100% NS
Elevated /Straub tail 20% 0% NS
Negative Geotaxis
Turns and climbs the grid 100% 100% NS
Touch escape
Escape response to a firm stroke 20% 25% NS
Escape response to a light stroke 80% 75% NS
Trunk curling
Absent 100% 100% NS
Visual Placing
Extension of forelimbs before contact 100% 100% NS
Preyer Reflex
Absent 20% 12,5% NS
Flick of pinnae 60% 87,5% NS
Startle 20% 0% NS
Pinna Reflex
Absent 40% 37,5% NS
Active retraction 40% 62,5% NS
Hyperactive, repetitive flicking 20% 0% NS
Corneal Reflex
Absent 10% 10% NS
Active blink 90% 90% NS
Provoked biting (absent) 100% 100% NS
Righting Reflex (present) 100% 100% NS
Toe Pinch
Moderate withdrawal 80% 100% NS
Brisk, rapid withdrawal 20% 0% NS
Data are given as percentage of animals showing a specific phenotype. NS: non
significant.
doi:10.1371/journal.pone.0017010.t001
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plasticity and memory storage seems to be determined by the
balance between protein phosphorylation and dephosphorylation
mediated by the kinase PKA and the phosphatase calcineurin. To
establish whether an excessive inhibitory constraint on endogenous
calcineurin in this balance may have a deleterious impact on
learning and memory in DS, we examined the effect of genetically
overexperessing RCAN1, and we have applied well-established
mouse behavioral tests addressing hippocampal function. More-
over, we also explored other learning and memory processes, such
as the recent memory, as tested in the passive avoidance paradigm.
Our data revealed neither motor nor sensory impairment in
TgRCAN1 or changes in any of the neurological parameters tested.
However, transgenic mice showed higher levels of activity in the
open field similar to what was has been described in other DS
models, such as Ts65Dn [16,23] and in DS persons. This
hyperactivity was not related to changes in emotionality, as it
did not affect the activity in the central part of the field.
However, a marked phenotype was attained in the visuo-spatial
learning paradigm. Although procedural learning was not affected
in the pre-training session, the acquisition of the allocentric
learning was markedly impaired in transgenic mice, thus
suggesting that RCAN1 overexpression is specifically affecting
hippocampal function. Those learning defects are specific since no
differences were observed in swimming speed or in the
motivational/motor aspects in the cued session. Moreover, the
Gallagher index was markedly altered indicating the use of non-
spatial learning strategies, and thus reinforcing the concept that
RCAN1 overexpression leads to a specific and marked learning
deficit in mice. However, in our experiments, TgRCAN1 mice did
not show any impairment in the removal session, thus indicating
that once consolidation has taken place, memory is well
established. The poorer execution of transgenic mice during the
acquisition phase was correlated with the searching trajectory of
the mice, that was significantly different, so that wild type mice
develop a clear spatial preference, whereas transgenic mice
distribute their activity similarly across all quadrants, indicating
impaired spatial learning.
Since the training procedure we have used involves an extensive
acquisition phase, we also tested recent memory in a one-trial
passive avoidance test to specifically targeting memory [24]. Again
TgRCAN1 mice did not show any impairment reinforcing the
concept that RCAN1 overexpression leads to specific alterations in
the acquisition process but does not influence memory.
Figure 2. Motor learning and coordination in the Rotarod test. Left panel: Motor learning curve of TgRCAN1 and wild type mice. TgRCAN1
did not show impairment in motor learning but when submitted to consecutive trials at increasing rotational speeds (7, 10, 14, 24 and 34 rpm)
performance in the more demanding trials was slightly improved in transgenic vs. wild type mice. Right panel: Acceleration trials. No differences
were detected between genotypes. Each data point represents the mean 6 S.E.M. *P#0.05. Abbreviations: NS: non significant; rpm: revolutions per
min.
doi:10.1371/journal.pone.0017010.g002
Figure 3. Visuo-spatial learning in the Morris water maze. Morris water maze performance of TgRCAN1 and wild type animals during the
learning sessions expressed as (left panel) latency (s) to reach the platform along the acquisition phase, cue and reversal sessions. A clear deficit was
observed in TgRCAN1 in all learning phases; (Right panel) Cumulative search-error on training trials and a learning index (Gallagher’s proximity
index) computed from the trials over the course of training. This measure relies on a computation of distance from the platform during the trial [17]
and clearly indicated the use of poorer learning strategies in transgenic mice. White squares represent wild types and black squares represent
TgRCAN1. Data are represented as mean 6 S.E.M. *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0017010.g003
The Role of RCAN1 in Down Syndrome
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e17010In conclusion, our results suggest that RCAN1 may contribute
to specific learning phenotypes in DS patients. We also propose
that excess of inhibition of endogenous calcineurin, which in turn
acts as an inhibitory constraint in the hippocampal phosphorila-
tion/dephosphorilation balance, has a significant impact on
learning but not on memory.
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